Premier Biomedical Inc
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors… Read more
Premier Biomedical Inc (BIEI) - Total Assets
Latest total assets as of March 2025: $3.55K USD
Based on the latest financial reports, Premier Biomedical Inc (BIEI) holds total assets worth $3.55K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Premier Biomedical Inc - Total Assets Trend (2010–2024)
This chart illustrates how Premier Biomedical Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Premier Biomedical Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Premier Biomedical Inc's total assets of $3.55K consist of 2.9% current assets and 97.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Premier Biomedical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Premier Biomedical Inc's current assets represent 2.9% of total assets in 2024, an increase from 2.5% in 2010.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2024, up from 2.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 97.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Premier Biomedical Inc Competitors by Total Assets
Key competitors of Premier Biomedical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Premier Biomedical Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Premier Biomedical Inc generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Premier Biomedical Inc is currently not profitable relative to its asset base.
Premier Biomedical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.05 | 0.05 |
| Quick Ratio | 0.00 | 0.04 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.56 Million | $ -1.84 Million | $ -1.84 Million |
Premier Biomedical Inc - Advanced Valuation Insights
This section examines the relationship between Premier Biomedical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 181.52 |
| Asset Growth Rate (YoY) | -56.1% |
| Total Assets | $3.23K |
| Market Capitalization | $585.78K USD |
Valuation Analysis
Premium Asset Valuation: The market values Premier Biomedical Inc's assets at a significant premium ( 181.52x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Premier Biomedical Inc's assets decreased by 56.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Premier Biomedical Inc (2010–2024)
The table below shows the annual total assets of Premier Biomedical Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.23K | -56.09% |
| 2023-12-31 | $7.35K | +134.49% |
| 2022-12-31 | $3.13K | 0.00% |
| 2021-12-31 | $3.13K | -31.88% |
| 2020-12-31 | $4.60K | -95.44% |
| 2019-12-31 | $100.94K | -38.82% |
| 2018-12-31 | $164.99K | -21.09% |
| 2017-12-31 | $209.08K | +436.56% |
| 2016-12-31 | $38.97K | -19.20% |
| 2015-12-31 | $48.23K | -60.02% |
| 2014-12-31 | $120.63K | +373.27% |
| 2013-12-31 | $25.49K | -41.26% |
| 2012-12-31 | $43.40K | +30.23% |
| 2011-12-31 | $33.32K | +119.37% |
| 2010-12-31 | $15.19K | -- |